Payment overview · 2025
General Payments
$664.87
15 reported records · 4 companies
Healthcare provider profile · identity verified
Pratima Patil, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · AUBURN, MA · NPI 1881141802
Verified facts
What the public records show
CMS Open Payments records show Pratima Patil, NP received $664.87 in general payments during 2025 across 15 reported records.
AstraZeneca Pharmaceuticals LP accounted for 76.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Paxlovid.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $510.97 | 76.8% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $65.27 | 9.8% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $63.35 | 9.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.28 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $664.87 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $305.40 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $205.57 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $63.35 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $40.38 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $25.28 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $24.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 33 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 56 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 17 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
132 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 276 | 73 |
| Furosemide | Furosemide | 253 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 231 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 204 | 51 |
| Trazodone Hcl | Trazodone Hcl | 149 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 143 | 46 |
| Eliquis | Apixaban | 132 | 24 |
| Lisinopril | Lisinopril | 122 | 28 |
| Losartan Potassium | Losartan Potassium | 120 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 103 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 32 |
| Gabapentin | Gabapentin | 91 | 27 |
| Omeprazole | Omeprazole | 91 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | 18 |
| Sertraline Hcl | Sertraline Hcl | 76 | 19 |
| Potassium Chloride | Potassium Chloride | 70 | 15 |
| Alprazolam | Alprazolam | 68 | 24 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 67 | 12 |
| Memantine Hcl | Memantine Hcl | 63 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 63 | 25 |
| Jardiance | Empagliflozin | 56 | 12 |
| Metformin Hcl | Metformin Hcl | 55 | 12 |
| Bumetanide | Bumetanide | 52 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 52 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 46 | suppressed |
| Simvastatin | Simvastatin | 43 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 25 |
| Nystatin | Nystatin | 42 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 39 | 14 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 38 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 34 | 14 |
| Tramadol Hcl | Tramadol Hcl | 34 | 15 |
| Allopurinol | Allopurinol | 33 | 12 |
| Atenolol | Atenolol | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 33 | suppressed |
| Ozempic | Semaglutide | 30 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 26 |
| Cephalexin | Cephalexin | 25 | 22 |
| Clonazepam | Clonazepam | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | 11 |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | 12 |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Travoprost | Travoprost | 17 | suppressed |
| Unifine Pentips Plus | Pen Needle, Diabetic | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Lactulose | Lactulose | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | 11 |
| Ramipril | Ramipril | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 12 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $664.87 · 15 records | AstraZeneca Pharmaceuticals LP | BREZTRI, FARXIGA, JARDIANCE, NURTEC ODT, PAXLOVID, Veozah | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error